RORC overexpression as a sign of Th17 lymphocytes accumulation in multiple myeloma bone marrow.


Journal

Cytokine
ISSN: 1096-0023
Titre abrégé: Cytokine
Pays: England
ID NLM: 9005353

Informations de publication

Date de publication:
10 2020
Historique:
received: 28 05 2020
revised: 06 07 2020
accepted: 13 07 2020
pubmed: 25 7 2020
medline: 17 11 2021
entrez: 25 7 2020
Statut: ppublish

Résumé

The role of the bone marrow microenvironment in supporting the proliferation and survival of the abnormal plasma cells in multiple myeloma (MM) is well established. Such microenvironment is rich of cytokines like IL-6, TGF-β, IL-1 and IL-23 which are known to promote the differentiation of Th17 lymphocytes, a T helper subpopulation. Th17 cells secrete IL-17, a cytokine involved in the pathophysiology of several auto-immune diseases. Yet, its involvement in cancers remains unclear. Herein, we aimed to try to understand the role of Th17 lymphocytes in multiple myeloma. Bone marrow samples were prospectively collected from 29 MM patients and 23 healthy bone marrow donors for allograft. Mononuclear bone marrow cells were isolated by Ficoll-Hypaque gradient and CD138

Identifiants

pubmed: 32707421
pii: S1043-4666(20)30226-X
doi: 10.1016/j.cyto.2020.155210
pii:
doi:

Substances chimiques

Interleukin-17 0
Nuclear Receptor Subfamily 1, Group F, Member 3 0
RORC protein, human 0
Receptors, Interleukin-17 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

155210

Informations de copyright

Copyright © 2020. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Ahlem Ben Hmid (A)

Laboratory of Clinical Immunology, Institut Pasteur de Tunis, 1002 Tunis, Tunisia; Faculté de Médecine de Tunis, Université Tunis El Manar, Tunis, Tunisia.

Oumayma Selmi (O)

Laboratory of Clinical Immunology, Institut Pasteur de Tunis, 1002 Tunis, Tunisia.

Raja Rekik (R)

Laboratory of Clinical Immunology, Institut Pasteur de Tunis, 1002 Tunis, Tunisia.

Hajer Lamari (H)

Faculté de Médecine de Tunis, Université Tunis El Manar, Tunis, Tunisia.

Imen Zamali (I)

Laboratory of Clinical Immunology, Institut Pasteur de Tunis, 1002 Tunis, Tunisia; Faculté de Médecine de Tunis, Université Tunis El Manar, Tunis, Tunisia.

Saloua Ladeb (S)

Bone Marrow Transplantation Center, Tunis, Tunisia.

Ines Safra (I)

Faculté de Médecine de Tunis, Université Tunis El Manar, Tunis, Tunisia; Laboratory of Clinical Hematology, Institut Pasteur de Tunis, 1002 Tunis, Tunisia.

Tarek Ben Othman (T)

Faculté de Médecine de Tunis, Université Tunis El Manar, Tunis, Tunisia; Bone Marrow Transplantation Center, Tunis, Tunisia.

Neila Ben Romdhane (N)

Faculté de Médecine de Tunis, Université Tunis El Manar, Tunis, Tunisia; Department of Clinical Hematology, La Rabta Hospital, Tunis, Tunisia.

Melika Ben Ahmed (M)

Laboratory of Clinical Immunology, Institut Pasteur de Tunis, 1002 Tunis, Tunisia; Faculté de Médecine de Tunis, Université Tunis El Manar, Tunis, Tunisia. Electronic address: melika.benahmed@pasteur.tn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH